Parth Rao, MD

Articles by Parth Rao, MD

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors

ByBenjamin P. Levy, MD,Parth Rao, MD,Daniel J. Becker, MD,Kevin Becker, MD

July 16th 2016

In this article, we review the available literature addressing the competing treatment strategies in EGFR-Positive Lung Cancer and attempt to clarify best treatment practices, including the emerging role of T790M-directed therapies.

Latest Updated Articles

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors
Published: July 16th 2016 | Updated:

Parth Rao, MD

Articles by Parth Rao, MD

Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors

Latest Updated Articles

Trending on CancerNetwork

Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC

Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors

FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars

Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap